Chronic Obstructive Pulmonary Disease Clinical Trial
— INTENSITYOfficial title:
A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
Status | Completed |
Enrollment | 1598 |
Est. completion date | March 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and: - a) Smoking history of at least 10 pack-years - b) Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and = 30% of the predicted normal value - c) Post-bronchodilator FEV1/FVC (forced vital capacity) < 70% Exclusion Criteria: - Patients who have received systemic corticosteroids or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening - Patients who have had a respiratory tract infection within 6 weeks prior to screening - Patients with concomitant pulmonary disease - Patients with a history of asthma - Patients with diabetes Type I or uncontrolled diabetes Type II - Any patient with lung cancer or a history of lung cancer - Patients with a history of certain cardiovascular comorbid conditions Other protocol-defined inclusion/exclusion criteria applied to the study. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Novartis Investigator Site | Feldbach | |
Austria | Novartis Investigator Site | Gänserndorf | |
Austria | Novartis Investigator Site | Hallein | |
Belgium | Novartis Investigator Site | Bruxelles | |
Belgium | Novartis Investigator Site | Gilly | |
Belgium | Novartis Investigator Site | Jambes | |
Belgium | Novartis Investigator Site | Jette | |
Belgium | Novartis Investigator Site | Liège | |
Belgium | Novartis Investigator Site | Montigny-le-tilleul | |
Belgium | Novartis Investigator Site | Oostende | |
Belgium | Novartis Investigator Site | Saint Vith | |
Belgium | Novartis Investigator Site | Yvoir | |
Canada | Novartis Investigator Site | Calgary | |
Canada | Novartis Investigative Site | Mississauga | |
Canada | Novartis Investigative Site | Moncton | |
Canada | Novartis Investigative Site | New Market | |
Canada | Novartis Investigative SIte | Quebec | |
Canada | Novartis Investigative Site | St-Romuald | |
Canada | Novartis Investigative Site | Sudbury | |
Colombia | Novartis Investigator Site | Barranquilla | |
Colombia | Novartis Investigator Site | Bogota | |
Colombia | Novartis Investigator Site | Medellin | |
Denmark | Novartis Investigator Site | Aalborg | |
Denmark | Novartis Investigator Site | Frederiksberg | |
Denmark | Novartis Investigator Site | Næstved | |
Denmark | Novartis Investigator Site | Roskilde | |
Denmark | Novartis Investigator Site | Sønderborg | |
Denmark | Novartis Investigator Site | Vaerlose | |
Denmark | Novartis Investigator Site | Viborg | |
Finland | Novartis Investigator Site | Helsinki | |
Finland | Novartis Investigator Site | Jyväskylä | |
Finland | Novartis Investigator Site | Lahti | |
Finland | Novartis Investigator Site | OYS | |
Finland | Novartis Investigator Site | Pori | |
Finland | Novartis Investigator Site | Turku | |
France | Novartis Investigative Site | Ambroise | |
France | Novartis Investigative Site | Antibes | |
France | Novartis Investigator Site | Beuvry | |
France | Novartis Investigator Site | Ferolles-Attily | |
France | Novartis Investigative Site | Montpellier | |
France | Novartis Investigator Site | Nantes | |
France | Novartis Investigative Site | Nice | |
France | Novartis Investigative Site | Nimes | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigator Site | Paris | |
France | Novartis Investigative Site | Pessac | |
France | Novartis Investigator Site | Pierre Benite | |
France | Novartis Investigative Site | Suresnes | |
France | Novartis Investigator Site | Vandoeuvre Les Nancys | |
Germany | Novartis Investigator Site | Bergisch Gladbach | |
Germany | Novartis Investigator Site | Berlin | |
Germany | Novartis Investigator Site | Bochum | |
Germany | Novartis Investigator Site | Bonn | |
Germany | Novartis Investigator Site | Buchholz | |
Germany | Novartis Investigator Site | Coburg | |
Germany | Novartis Investigator Site | Dueren | |
Germany | Novartis Investigator Site | Eggenfelden | |
Germany | Novartis Investigator Site | Eschwege | |
Germany | Novartis Investigator Site | Euskirchen | |
Germany | Novartis Investigator Site | Freudenberg | |
Germany | Novartis Investigator Site | Fürth | |
Germany | Novartis Investigator Site | Gelsenkirchen | |
Germany | Novartis Investigator Site | Gummersbach | |
Germany | Novartis Investigator Site | Hagen | |
Germany | Novartis Investigator Site | Halle | |
Germany | Novartis Investigator Site | Hamburg | |
Germany | Novartis Investigator Site | Hannover | |
Germany | Novartis Investigator Site | Hoyerswerda | |
Germany | Novartis Investigator Site | Kassel | |
Germany | Novartis Investigative Site | Landsberg | |
Germany | Novartis Investigator Site | Leipzig | |
Germany | Novartis Investigator Site | Mainz | |
Germany | Novartis Investigator Site | Munich | |
Germany | Novartis Investigator Site | Oranienburg | |
Germany | Novartis Investigator Site | Radebeul | |
Germany | Novartis Investigator Site | Ratingen | |
Germany | Novartis Investigator Site | Ruhmannsfelden | |
Germany | Novartis Investigator Site | Rüsselsheim | |
Germany | Novartis Investigator Site | Solingen | |
Germany | Novartis Investigator Site | Stockach | |
Germany | Novartis Investigator Site | Teterow | |
Germany | Novartis Investigator Site | Vilshofen | |
Germany | Novartis Investigator Site | Wallerfing | |
Germany | Novartis Investigator Site | Wissen | |
Greece | Novartis Investigator Site | Athens | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigator Site | Budapest | |
Hungary | Novartis Investigator Site | Debrecen | |
Hungary | Novartis Investigative Site | Farkasgyepu | |
Hungary | Novartis Investigative Site | Godollo | |
Hungary | Novartis Investigator Site | Szolnok | |
Israel | Novartis Investigator Site | Haifa | |
Israel | Novartis Investigator Site | Petach-Tikva | |
Italy | Novartis Investigator Site | Ancona | |
Italy | Novartis Investigator Site | Foggia | |
Italy | Novartis Investigative Site | Milano | |
Italy | Novartis Investigator Site | Milano | |
Italy | Novartis Investigative Site | Pavia | |
Italy | Novartis Investigator Site | Pavia | |
Italy | Novartis Investigative Site | Pisa | |
Italy | Novartis Investigator Site | Pisa | |
Mexico | Novartis Investigative Site | Huxquilucan | |
Mexico | Novartis Investigator Site | Mexico City | |
Mexico | Novartis Investigative Site | San Luis Potosi | |
Norway | Novartis Investigative Site | Ålesund | |
Norway | Novartis Investigator Site | Ålesund | |
Norway | Novartis Investigator Site | Drammen | |
Norway | Novartis Investigator Site | Follebu | |
Norway | Novartis Investigative Site | Kongsberg | |
Norway | Novartis Investigator Site | Kongsberg | |
Norway | Novartis Investigator Site | Kongsvinger | |
Norway | Novartis Investigator Site | Lierskogen | |
Norway | Novartis Investigative Site | Oslo | |
Norway | Novartis Investigator Site | Oslo | |
Norway | Novartis Investigator Site | Sandvika | |
Norway | Novartis Investigative Site | Skedsmokorset | |
Norway | Novartis Investigator Site | Stavanger | |
Norway | Novartis Investigative Site | Trondheim | |
Norway | Novartis Investigator Site | Trondheim | |
Poland | Novartis Investigator Site | Gdansk | |
Poland | Novartis Investigator Site | Katowice | |
Poland | Novartis Investigative Site | Krakow | |
Poland | Novartis Investigator Site | Krakow | |
Poland | Novartis Investigator Site | Piekary Slaskie | |
Poland | Novartis Investigator Site | Warszawa | |
Poland | Novartis Investigator Site | Wroclaw | |
Russian Federation | Novartis Investigator Site | Barnaul | |
Russian Federation | Novartis Investigator Site | Ekaterinburg | |
Russian Federation | Novartis Investigator Site | Kazan | |
Russian Federation | Novartis Investigator Site | Novosibirsk | |
Russian Federation | Novartis Investigator Site | Petrozavodsk | |
Russian Federation | Novartis Investigator Site | Ryazan | |
Russian Federation | Novartis Investigative Site | Saint-Petersburg | |
Russian Federation | Novartis Investigator Site | Saint-Petersburg | |
Russian Federation | Novartis Investigator Site | Samara | |
Slovakia | Novartis Investigator Site | Bratislava | |
Slovakia | Novartis Investigative Site | Kosice | |
Slovakia | Novartis Investigator Site | Kosice | |
Slovakia | Novartis Investigator Site | Kralovsky Chlmec | |
Slovakia | Novartis Investigator Site | Nitra | |
Slovakia | Novartis Investigative Site | Presov | |
Slovakia | Novartis Investigator Site | Zvolen | |
Spain | Novartis Investigative Site | Alcorcón | |
Spain | Novartis Investigator Site | Alicante | |
Spain | Novartis Investigator Site | Badalona | |
Spain | Novartis Investigative Site | Barcelona | |
Spain | Novartis Investigative Site | Begonte | |
Spain | Novartis Investigator Site | Burgos | |
Spain | Novartis Investigator Site | Caceres | |
Spain | Novartis Investigator Site | Canet de Mar | |
Spain | Novartis Investigative Site | Fuenlabrada | |
Spain | Novartis Investigative Site | Girona | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigator Site | Mataro | |
Spain | Novartis Investigator Site | Plasencia | |
Spain | Novartis Investigative Site | Ponferrada | |
Spain | Novartis Investigative Site | Pontevedra | |
Spain | Novartis Investigator Site | Prat de Llobregat | |
Spain | Novartis Investigative Site | Santander | |
Spain | Novartis Investigative Site | Valencia | |
Spain | Novartis Investigative Site | Vila-real | |
Switzerland | Novartis Investigator Site | Basel | |
Switzerland | Novartis Investigator Site | Bellinzona | |
Switzerland | Novartis Investigator Site | Lugano | |
Switzerland | Novartis Investigator Site | Muenchenstein | |
Switzerland | Novartis Investigative Site | Zuerich | |
Turkey | Novartis Investigator Site | Altunizade | |
Turkey | Novartis Investigator Site | Ankara | |
Turkey | Novartis Investigative Site | Aydin | |
Turkey | Novartis Investigator Site | Büyükçekmece / Ýstanbul | |
Turkey | Novartis Investigative Site | Fatih / Istanbul | |
Turkey | Novartis Investigator Site | Istanbul | |
Turkey | Novartis Investigator Site | Kahramanmaras | |
Turkey | Novartis Investigative Site | Mecidiyekoy/Istanbul | |
Turkey | Novartis Investigative Site | Mersin | |
Turkey | Novartis Investigative Site | Soke / Aydin | |
Turkey | Novartis Investigative Site | Yenisehir/Izmir | |
United Kingdom | Novartis Investigator Site | Ash Vale | |
United Kingdom | Novartis Investigator Site | Ashford | |
United Kingdom | Novartis Investigator Site | Bolton | |
United Kingdom | Novartis Investigator Site | Boscastle | |
United Kingdom | Novartis Investigator Site | Bradford | |
United Kingdom | Novartis Investigator Site | Chertsey | |
United Kingdom | Novartis Investigator Site | East Horsley | |
United Kingdom | Novartis Investigator Site | Newcastle-upon-Tyne | |
United Kingdom | Novartis Investigator Site | Plymouth | |
United Kingdom | Novartis Investigator Site | Watford | |
United States | Novartis Investigative Site | Albany | New York |
United States | Novartis Investigator Site | Anaheim | California |
United States | Novartis Investigative Site | Birmingham | Alabama |
United States | Novartis Investigative Site | Charlotte | North Carolina |
United States | Novartis Investigative Site | Columbus | Ohio |
United States | Novartis Investigative Site | Evansville | Indiana |
United States | Novartis Investigator Site | Fort Collins | Colorado |
United States | Novartis Investigative Site | Henderson | Nevada |
United States | Novartis Investigator Site | Jasper | Alabama |
United States | Novartis Investigative Site | Lafayette | Louisiana |
United States | Novartis Investigative Site | Larchmont | New York |
United States | Novartis Investigative Site | Lincoln | Nebraska |
United States | Novartis Investigative Site | New York | New York |
United States | Novartis Investigator Site | Normal | Illinois |
United States | Novartis Investigative Site | Phoenix | Arizona |
United States | Novartis Investigative Site | Richmond | Virginia |
United States | Novartis Investigative Site | San Antonio | Texas |
United States | Novartis Investigative Site | South Miami | Florida |
United States | Novartis Investigative Center | St Charles | Missouri |
United States | Novartis Investigative Site | St Louis | Missouri |
United States | Novartis Investigator Site | Stockton | California |
United States | Novartis Investigative Site | Topeka | Kansas |
United States | Novartis Investigative Site | Tucson | Arizona |
United States | Novartis Investigator Site | Walnut Creek | California |
United States | Novartis Investigator Site | Wheat Ridge | Colorado |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Austria, Belgium, Canada, Colombia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Norway, Poland, Russian Federation, Slovakia, Spain, Switzerland, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Trough Forced Expiratory Volume in 1 Second (FEV1) at End of Treatment (Week 12) | Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | End of treatment (Week 12) | No |
Secondary | Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of Treatment (Week 12) | Spirometry was conducted according to internationally accepted standards. FEV1 was measured at 5 and 30 minutes; and 1, 2, and 4 hours post-dose on Week 12. Standardized FEV1 AUC (5 minutes-4 hour) post-dose at week 12 was calculated based on the trapezoidal rule, and was adjusted for the area per time unit by using the scheduled time of measurements for FEV1. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | 5 minutes to 4 hours post-dose at the end of treatment (week 12) | No |
Secondary | Transition Dyspnea Index (TDI) Focal Score After 12 Weeks of Treatment | TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9 with a negative score indicating a deterioration from baseline. A 1 unit difference in the TDI focal score is clinically significant. Mixed model used baseline dyspnea index, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | 12 weeks | No |
Secondary | Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 Weeks of Treatment | SGRQ is a health related quality of life questionnaire consisting of 50 items in three domains: symptoms (frequency and severity), activity (that cause or are limited by breathlessness) and impacts (social functioning & psychological disturbances resulting from airway disease). The total score is 0 to 100 with a higher score indicating greater impairment of health status. Mixed model used baseline SGRQ, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | 12 weeks | No |
Secondary | Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (From Day 1 to Week 12) | Participants recorded the number of puffs of rescue medication taken in the previous 12 hours each morning and evening in an electronic diary. The number of puffs per day over the 12 weeks of treatment was divided by the number of days to derive the mean number per day of puffs of rescue medication for each participant. Mixed model used baseline number of puffs per day of rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | Baseline, up to 12 weeks | No |
Secondary | Change From Baseline in the Mean Number Per Day of Daytime Puffs of Rescue Medication Over the Study Duration (From Day 1 to Week 12) | Participants recorded the number of puffs of rescue medication taken in the previous 12 hours each evening in an electronic diary. The number of daytime puffs per day over the 12 weeks of treatment was divided by the number of days to derive the mean number per day of daytime puffs of rescue medication for each participant. Mixed model used baseline number of daytime puffs per day of rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | Baseline, up to 12 weeks | No |
Secondary | Change From Baseline in the Mean Number Per Day of Nighttime Puffs of Rescue Medication Over the Study Duration (From Day 1 to Week 12) | Participants recorded the number of puffs of rescue medication taken in the previous 12 hours each morning in an electronic diary. The number of nighttime puffs per day over the 12 weeks of treatment was divided by the number of days to derive the mean number per day of nighttime puffs of rescue medication for each participant. Mixed model used baseline number of nighttime puffs per day of rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | Baseline, up to 12 weeks | No |
Secondary | Percentage of Days With no Rescue Medication Use During the 12 Weeks of Treatment | A day with no rescue medication was defined as any day in the diary that the participant used no puffs of rescue medication. The percentage of days with no rescue medication was calculated by dividing the number of days with no rescue medication over the 12 week treatment period by the number of evaluable days and multiplying by 100. Mixed model used baseline percentage of days with no rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates. | Up to 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|